Natco Pharma’s marketing partner Alvogen has received the final approval and is the first to market the generic equivalent to oseltamivir phosphate, 6 mg/ml powder for oral suspension in the United States. In December 2016, Alvogen launched the first generic equivalent to oseltamivir phosphate capsules in the United States.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
